Table 2

Weighted Averages Preseries and Postseries for Individual Topics

TopicPreseries-weighted average of trainee comfort level (n = 72, scale 1–5)Postseries-weighted average of trainee comfort level (n = 26, scale 1–5)Preseries-weighted average of program director expected value (n = 22, scale 1–5)Postseries-weighted average of program director impression of educational value (n = 12, scale 1–5)
Advanced MRI techniques for MS/neuroinflammation2.743.774.554.2
Anti-NMDA receptor encephalitis and mechanisms of disease3.384.124.594.45
Autoimmune myelitis and its mimics3.324.124.774.55
B-cell and autoantibody-mediated pathogenesis in CNS autoimmunity3.094.04.824.36
Basic science of remyelination2.533.584.364.1
Clinical trial design2.553.424.754.27
Emerging autoimmune diseases2.883.854.734.6
Ethnicity and diversity in the MS experience2.923.814.414.45
Hematopoietic and mesenchymal stem-cell therapy for MS2.313.544.434.09
Immunobiology of MS2.933.854.824.44
Integrative medicine and cannabis2.543.424.183.6
Lab techniques and tools for understanding antibody-mediated diseases2.613.654.54.45
Neurorheumatology: Neurosarcoidosis, CNS vasculitis, CNS lupus, neuro-Beçhet's2.783.844.824.64
Pediatric MS2.743.734.554.4
PML and opportunistic infections3.123.964.554.5
Progressive MS: challenges in finding and demonstrating effective therapies3.24.124.734.42
Symptomatic management of advanced MS3.534.274.643.8
Urological issues and their management in MS2.613.734.414.4
  • Abbreviations: MS = multiple sclerosis; PML = progressive multifocal leukoencephalopathy.